Mineralys Therapeutics Inc

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea, and other diseases driven by dysregulated aldosterone. Its lead product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor that reduces aldosterone levels by inhibiting CYP11B2. The company has completed six late-stage clinical trials of lorundrostat, including two pivotal registrational trials (Phase 3 Launch-HTN and Phase 2 Advance-HTN), and has submitted a New Drug Application to the FDA with a PDUFA target date of December 22, 2026. Mineralys is a pre-revenue, clinical-to-commercial stage company preparing for its first potential product launch. The company was founded by Catalys Pacific and trades on Nasdaq under the ticker MLYS. Updated Aug 11, 2026